Evogene Ltd. EVGN
NASDAQ
| 06/30/2026 | 12/31/2025 | 06/30/2025 | 03/31/2025 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 347.00K | 314.00K | 534.00K | 2.34M | 3.77M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 347.00K | 314.00K | 534.00K | 2.34M | 3.77M |
| Cost of Revenue | 206.00K | 2.28M | 136.00K | 1.52M | 511.00K |
| Gross Profit | 141.00K | -1.97M | 398.00K | 826.00K | 3.26M |
| SG&A Expenses | 1.15M | 1.20M | 1.19M | 1.57M | 2.38M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -27.00K | -- | -- | -- |
| Total Operating Expenses | 2.45M | 5.28M | 2.17M | 5.56M | 7.95M |
| Operating Income | -2.11M | -4.97M | -1.64M | -3.22M | -4.18M |
| Income Before Tax | -1.27M | -5.34M | -2.19M | -1.90M | -3.86M |
| Income Tax Expenses | -4.00K | 0.00 | -- | -- | -5.00K |
| Earnings from Continuing Operations | -1.26M | -5.34M | -2.19M | -1.90M | -3.86M |
| Earnings from Discontinued Operations | -506.00K | -16.00K | -2.49M | -1.09M | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -1.00K | 45.00K | 219.00K | 402.00K | -126.00K |
| Net Income | -1.77M | -5.31M | -4.46M | -2.59M | -3.98M |
| EBIT | -2.11M | -4.97M | -1.64M | -3.22M | -4.18M |
| EBITDA | -1.97M | -4.70M | -1.44M | -2.91M | -3.52M |
| EPS Basic | -0.14 | -0.61 | -0.62 | -0.38 | -0.81 |
| Normalized Basic EPS | -0.06 | -0.36 | -- | -- | -0.52 |
| EPS Diluted | -0.14 | -0.61 | -0.62 | -0.38 | -0.81 |
| Normalized Diluted EPS | -0.06 | -0.36 | -- | -- | -0.52 |
| Average Basic Shares Outstanding | 12.20M | 8.72M | 7.01M | 6.80M | 4.89M |
| Average Diluted Shares Outstanding | 12.20M | 8.72M | 7.01M | 6.80M | 4.89M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |